Daniel Swerdlow (@DanielSwerdlow) profile picture
London, UK
Joined March 2012
Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)Photo by Daniel Swerdlow (@DanielSwerdlow)
Thank you to Mark Edbrooke, @DanielSwerdlow, @DrCathyWilson and Peter Oliver for your insightful talks at yesterday's #CamNTF event! Your expertise in nucleic acid therapeutics is truly inspiring. #Grateful #FutureOfHealthcare
1
2
186
We’re hosting our first meetup for Product People and those involved in early R&D in pharma/biotech on June 18th in London Kings Cross. Come down and contribute to the discussion on how Product can bring value to the drug development pipeline! 🚀 eventbrite.co.uk/e/the-produ…
2
1
266
Drug discovery people in pharma and biotech - here's something for you: @productcompound Come and learn what product people and product mindset can bring to the work we do theproductcompound.com linkedin.com/groups/12971184…
1
3
445
Calling #oligonucleotide therapeutics folks - please submit topics you would like to see on the agenda at the DIA oligo-based therapeutics meeting in Oct 2024 - we're putting the meeting together now and it's going to be a good one! diaglobal.org/conference-lis… #Oligo24
3
211
Yesterday we announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 for #AATD. WVE-006 is the first #RNAediting candidate ever to be evaluated in the humans. Click below to read more. $WVE

1
1
7
1,264
Come and join my group in Milan! Five year research position. Open to multiple profiles. Machine learning researchers interested in large-scale imaging, genetics and health-research apply! Attractive 90% tax exemption for people new or returning to Italy. careers.humantechnopole.it/o…
20
1
31
7,144
Great to be back at #EASCongress2022 in person in Milan. Looking forward to a stimulating three days @SilenceTheraPlc @society_eas
6
Daniel Swerdlow retweeted
In a phase 1 study of participants with elevated Lp(a) levels and no known cardiovascular disease, the siRNA SLN360 was well tolerated, and a dose-dependent lowering of plasma Lp(a) concentrations was observed. ja.ma/3qU3kQB #ACC22
6
15
Daniel Swerdlow retweeted
Lipoprotein(a) has been deemed important but inactionable for years. In addition to other meds in development, new data from ⁦@SilenceTheraPlc⁩ siRNA at #ACC22 in healthy participants with increased lipoprotein(a) notes suppression up to 98%! ⁦@TheFHFoundation⁩
2
8
1
37
Attention #ACC22 early birds! Our APOLLO phase 1 #Lpa data will be presented this morning at 8:45 ET, during the JAMA Late-Breaking Clinical Trials session. Grab a coffee and tune in. #SilenceIsGOLDen
4
7
Daniel Swerdlow retweeted
The #lipid lowering world is changing before our eyes! #siRNA in the hyperLPA #therapy. Looking forward to seeing the results of the APOLLO trial. @SilenceTheraPlc @rblument1 @drpablocorral @cpcannon @Lpa_Doc @pabeda1 @VietHeartPA @DrMarthaGulati @FeliceGragnano @MeralKayikcoglu
2
11
4
49
Tomorrow, Dr. Steven E. Nissen of the @ClevelandClinic will be presenting the phase 1 APOLLO Trial data for our investigational siRNA therapy for high #Lpa. Get up to speed on the science: https://teapawt.org/t.co/3SrDSjidzC #SilenceIsGOLDen
1
5
Today is the first ever #LpaAwarenessDay. We’re grateful to have met many members of this disease community through our Lp(a) clinical program. We are committed to using our gene-silencing science to better serve your needs: https://teapawt.org/t.co/dJcbYzT4Pt
3
9
Today is #LpaAwarenessDay. Lipoprotein (a) is an inherited condition that affects 1 in 5 people and increases your risk of cardiovascular disease. Talk to your doctor about testing for Lp(a) and how to reduce other #CVD 💔 risk factors. test.thefhfoundation.org #KnowLpa
3
9
Great to see a showcase of the UK as an AI powerhouse at @FoundSciTech #fstAI. Proud that @SilenceTheraPlc is putting AI/ML into action for siRNA drug discovery and development
2
#ICYMI: $SLN announced positive phase 1 data of our #genesilencing treatment, which aims to address the unmet need of those living with high levels of #Lipoproteina. Learn more at our late-breaking #ACC22 presentation: https://teapawt.org/t.co/frw8fOJzxg #SilenceisGOLDen
3
4
Fantastic news!! #sirna #lpa
We are excited to announce positive Phase 1 data of our gene silencing therapy, which aims to silence Lipoproteina (#Lpa), a risk factor for #heartdisease. Read more here: https://teapawt.org/t.co/54GZ9qgn0f #SilenceisGOLDen #AmericanHeartMonth #biotech $SLN
1
2
We are excited to announce positive Phase 1 data of our gene silencing therapy, which aims to silence Lipoproteina (#Lpa), a risk factor for #heartdisease. Read more here: https://teapawt.org/t.co/54GZ9qgn0f #SilenceisGOLDen #AmericanHeartMonth #biotech $SLN
3
3
10